Xintela AB (XINT) AI Stock Analysis

• Market Cap: kr253.21M
• Dividend Yield: N/A
• Average Volume (3M): 554.92K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.73
• Revenue Growth: -7.68%
• EPS Growth: 17.93%
• Country: SE
• Employees: 21
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.01
• Shares Outstanding: 861,266,850
• 10 Day Avg. Volume: 503,836
• 30 Day Avg. Volume: 554,918
• PEG Ratio: 0.10
• Price to Book (P/B): -31.80
• Price to Sales (P/S): 44.88
• P/FCF Ratio: -4.65
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 49 Neutral
• Price Target: kr0.29 ▲(4.64% Upside)

The score is held down primarily by weak financial performance (shrinking revenue, large ongoing losses, heavy cash burn, and deteriorating negative equity). Technical indicators provide some offset with improving short-term momentum, but valuation remains constrained by negative earnings (negative P/E).

Positive Factors

No reported debt

Zero reported debt materially lowers financial leverage and insolvency risk, preserving strategic optionality for licensing, partnerships or equity raises. This structural strength improves long-term resilience and flexibility for capital strategy despite ongoing losses.

Strong gross profit per revenue

Consistently strong gross profit relative to revenue suggests the company's products or processes have solid unit economics. If management can scale sales, margin leverage could accelerate profitability and support durable operating improvements as volumes grow.

Focused R&D platform

Concentration on the integrin α10β1 platform provides a clear scientific niche across orthopedics and oncology, enabling multiple therapeutic and diagnostic pathways. This focused platform can create durable IP, partnership opportunities, and long-term value if clinical progress continues.

Negative Factors

Heavy cash burn

Ongoing TTM operating and free cash outflows around -37M create persistent funding pressure, forcing repeated capital raises or dilutive deals. This structural cash burn constrains runway, slows development programs, and increases dependency on external financing over multiple quarters.

Negative shareholders' equity

Meaningfully negative shareholders' equity and declining assets reflect accumulated losses and eroded balance-sheet flexibility. Structurally, negative equity limits borrowing capacity, raises solvency concerns, and can complicate large partnerships or commercialization investments over the medium term.

Small, shrinking revenue and large losses

Very small TTM revenue down nearly 40% alongside ~-42M operating losses indicates the business is not commercially validated. Persistent losses relative to revenue mean the company must rapidly scale sales or materially cut burn to reach sustainable operations in the medium term.

Xintela AB Business Overview & Revenue Model

Company Description

Xintela AB (publ), a biomedical company, operates in the fields of regenerative medicine and cancer, focusing on cartilage damage and brain tumors. The company develops products based on XINMARK, a patented marker technology that identifies and selects a range of stem cells, which can develop cartilage cells. It is also developing XSTEM a stem cell product that is in clinical development phase for the treatment of knee osteoarthritis and difficult-to-heal leg ulcers; and EQSTEM, a stem cell product for the treatment of joint diseases in horses, as well as focuses on the preclinical development of therapeutic antibodies for aggressive cancers, including brain tumor glioblastoma and triple negative breast cancer. Xintela AB (publ) was founded in 2009 and is based in Lund, Sweden.

How the Company Makes Money

Xintela AB primarily generates revenue through the development and commercialization of its proprietary cell therapy products and targeted cancer treatments. The company earns money by partnering with pharmaceutical companies and research institutions to co-develop therapies, licensing its technology, and potentially through future product sales once regulatory approvals are secured. Significant factors contributing to its earnings include collaborative agreements, research grants, and strategic partnerships that support the advancement of its clinical programs. Additionally, Xintela may benefit from milestone payments and royalties from commercialized products developed using its technology.

Xintela AB Financial Statement Overview

Summary

Weak fundamentals: very small and sharply declining TTM revenue (-39.9%), deeply negative EBIT/net income (about -42M), and heavy ongoing cash burn (TTM OCF/FCF around -37M). No debt helps, but equity is meaningfully negative and worsening, indicating limited financial flexibility and reliance on external funding.

Income Statement

TTM (Trailing-Twelve-Months) revenue is small (2.96M) and down sharply versus the prior annual period (revenue growth -39.9% TTM after +53.0% in 2024), indicating a volatile and still-developing commercial base. Profitability remains very weak: TTM EBIT and net income are deeply negative (-41.97M and -42.28M), with a highly negative net margin, showing operating costs far exceed revenue. A positive is that gross profit is strong relative to revenue in the periods with revenue, but it is not translating into bottom-line improvement.

Balance Sheet

The balance sheet shows no total debt in the most recent periods (TTM and 2024), reducing financial leverage risk. However, shareholders’ equity has turned meaningfully negative in TTM (-27.88M) after already being negative in 2024 (-5.95M), which is a major weakness and points to accumulated losses and reduced balance sheet flexibility. Total assets have also declined versus prior years (9.08M TTM vs 24.80M in 2024), suggesting shrinking resources available to fund operations.

Cash Flow

Cash burn remains heavy: TTM operating cash flow and free cash flow are both around -37.0M, indicating ongoing funding needs. Free cash flow improved versus 2024 (positive free cash flow growth of ~26%), but it is still materially negative. Cash flow is roughly in line with reported losses (free cash flow to net income ~1.00), which suggests losses are translating into cash outflows rather than being offset by working-capital or non-cash items.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.96M	4.21M	78.00K	0.00	0.00	0.00
Gross Profit	2.81M	4.21M	78.00K	-3.79M	-3.50M	-3.57M
EBITDA	-41.36M	-38.90M	-53.47M	-65.28M	-57.11M	-30.33M
Net Income	-42.28M	-39.19M	-54.08M	-66.22M	-58.93M	-52.92M
Balance Sheet
Total Assets	9.08M	24.80M	18.39M	24.52M	24.74M	48.51M
Cash, Cash Equivalents and Short-Term Investments	3.38M	16.68M	7.81M	8.34M	9.94M	33.60M
Total Debt	0.00	0.00	0.00	0.00	0.00	10.90M
Total Liabilities	36.95M	30.75M	14.02M	18.74M	20.80M	20.91M
Stockholders Equity	-27.88M	-5.95M	4.38M	5.78M	3.95M	27.61M
Cash Flow
Free Cash Flow	-37.05M	-40.70M	-53.22M	-39.60M	-44.15M	-21.71M
Operating Cash Flow	-36.98M	-40.70M	-53.12M	-39.49M	-42.89M	-21.33M
Investing Cash Flow	0.00	0.00	-104.00K	-27.52M	-1.20M	-329.00K
Financing Cash Flow	39.20M	50.09M	51.79M	64.56M	20.43M	54.85M

Xintela AB Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.28
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:XINT, the sentiment is Negative. The current price of 0.28 is below the 20-day moving average (MA) of 0.31, above the 50-day MA of 0.28, and below the 200-day MA of 0.37, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 48.06 is Neutral, neither overbought nor oversold. The STOCH value of 26.71 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:XINT.

Xintela AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
XINT	49 Neutral	kr253.21M	-4.59	―	―	-7.68%	17.93%
ELIC	47 Neutral	kr259.67M	-15.57	-48.30%	―	―	52.96%
IRLAB.A	46 Neutral	kr153.91M	-1.15	-199.86%	―	69.03%	23.10%
ISOFOL	44 Neutral	kr187.92M	-2.33	-51.35%	―	―	-34.02%
MODTX	43 Neutral	kr37.70M	-1.37	-166.94%	―	―	-19.35%
ACTI	41 Neutral	kr109.66M	-1.29	-1291.15%	―	―	28.54%